Axsome Therapeutics, Inc.

Axovant Gene Therapies Misses on EPS, Stock Down 12.57%

Axovant Gene Therapies reported a significant loss per share, which was much worse than expected, contributing to a sharp decline in stock price. The lack of revenue information and guidance may raise concerns among investors about the company's financial health and future prospects. The market reacted negatively, reflecting uncertainty about the company's direction and performance in the coming quarters.